Literature DB >> 18926093

Esophageal cancer.

Jaffer A Ajani1, James S Barthel, Tanios Bekaii-Saab, David J Bentrem, Thomas A D'Amico, Charles S Fuchs, Hans Gerdes, James A Hayman, Lisa Hazard, David H Ilson, Lawrence R Kleinberg, Mary Frances McAleer, Neal J Meropol, Mary F Mulcahy, Mark B Orringer, Raymond U Osarogiagbon, James A Posey, Aaron R Sasson, Walter J Scott, Stephen Shibata, Vivian E M Strong, Stephen G Swisher, Mary Kay Washington, Christopher Willett, Douglas E Wood, Cameron D Wright, Gary Yang.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18926093

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  9 in total

1.  Diagnosis and management of Barrett's esophagus for the endoscopist.

Authors:  Sagar S Garud; Steven Keilin; Qiang Cai; Field F Willingham
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

Review 2.  Endoscopic options for early stage esophageal cancer.

Authors:  Pari M Shah; Hans Gerdes
Journal:  J Gastrointest Oncol       Date:  2015-02

3.  Treatment modalities for T1N0 esophageal cancers: a comparative analysis of local therapy versus surgical resection.

Authors:  Mark F Berry; Josiane Zeyer-Brunner; Anthony W Castleberry; Jeremiah T Martin; Beat Gloor; Ricardo Pietrobon; Thomas A D'Amico; Mathias Worni
Journal:  J Thorac Oncol       Date:  2013-06       Impact factor: 15.609

4.  Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience.

Authors:  Panteleimon Kountourakis; Arlene M Correa; Wayne L Hofstetter; Jeffrey H Lee; Manoop S Bhutani; David C Rice; Ritsuko Komaki; Dipen M Maru; William A Ross; Ara Vaporciyan; Stephen G Swisher; Jaffer A Ajani
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

5.  Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy.

Authors:  Akihiro Suzuki; Lianchun Xiao; Yuki Hayashi; Homer A Macapinlac; James Welsh; Steven H Lin; Jeffrey H Lee; Manoop S Bhutani; Dipen M Maru; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani
Journal:  Cancer       Date:  2011-03-31       Impact factor: 6.860

Review 6.  Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients.

Authors:  Yuichiro Hiura; Shuji Takiguchi; Kazuyoshi Yamamoto; Yukinori Kurokawa; Makoto Yamasaki; Kiyokazu Nakajima; Hiroshi Miyata; Yoshiyuki Fujiwara; Masaki Mori; Yuichiro Doki
Journal:  Int J Clin Oncol       Date:  2011-07-20       Impact factor: 3.402

7.  Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort.

Authors:  N K S Cheedella; A Suzuki; L Xiao; W L Hofstetter; D M Maru; T Taketa; K Sudo; M A Blum; S H Lin; J Welch; J H Lee; M S Bhutani; D C Rice; A A Vaporciyan; S G Swisher; J A Ajani
Journal:  Ann Oncol       Date:  2012-12-17       Impact factor: 32.976

8.  Minimally invasive esophagectomy.

Authors:  Christy M Dunst; Lee L Swanström
Journal:  J Gastrointest Surg       Date:  2009-09-30       Impact factor: 3.452

9.  Current treatment options for the management of esophageal cancer.

Authors:  Mark R Mawhinney; Robert E Glasgow
Journal:  Cancer Manag Res       Date:  2012-11-02       Impact factor: 3.989
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.